Literature DB >> 10899355

The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin.

M K Ramjee1, I M Henderson, S B McLoughlin, A Padova.   

Abstract

Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, is active against a number of the serine proteases involved in coagulation. This has been proposed as the basis of its anticoagulant activity. We investigated the reaction of Nafamostat with bovine pancreatic trypsin as a model system. It was shown to act as a time-dependent competitive inhibitor, and the inhibition constants for the binding of Nafamostat to trypsin (i.e., Ki) and the overall inhibition constants (i.e., Ki*) were calculated to be 11.5 microM and 0.4+/-0.14 nM, respectively. The second-order rate constant for the reaction was 4.5+/-0.19x10(5) M(-1)s(-1), and the product released following the acylation step, 6-amidino2-naphthol, showed mixed-type inhibition. The competitive (Kic) and uncompetitive (Kiu) inhibition constants were 14.7 microM and 19.5 microM, respectively. Formation of the acyl-enzyme intermediate was dissected into at least two steps, with rates of 0.9 s(-1) and 195 s(-1). The deacylation step was relatively much slower (3.2+/-0.19x10(-5) s(-1), enabling the mass spectroscopic analysis of the acyl-enzyme intermediate, which confirmed the covalent attachment of 4-guanidinobenzoic acid to trypsin. The product of the deacylation step, 4-guanidinobenzoic acid, showed no inhibition up to a concentration of 200 microM. These data strongly suggest that while Nafamostat is a potent inhibitor of trypsin, it is actually an extremely poor substrate, and that apparent inhibition is due to the competitive formation of a very stable acyl-enzyme intermediate, analogous to some other active site titrants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899355     DOI: 10.1016/s0049-3848(00)00206-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

Review 1.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

2.  Transmembrane Protease Serine 2 Proteolytic Cleavage of the SARS-CoV-2 Spike Protein: A Mechanistic Quantum Mechanics/Molecular Mechanics Study to Inspire the Design of New Drugs To Fight the COVID-19 Pandemic.

Authors:  Luís M C Teixeira; João T S Coimbra; Maria João Ramos; Pedro Alexandrino Fernandes
Journal:  J Chem Inf Model       Date:  2022-05-12       Impact factor: 6.162

3.  A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.

Authors:  Toshiaki Sendo; Yoshinori Itoh; Takeshi Goromaru; Tomoko Sumimura; Mami Saito; Keisei Aki; Takahisa Yano; Ryozo Oishi
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  Structure of human prostasin, a target for the regulation of hypertension.

Authors:  Keith W Rickert; Paul Kelley; Noel J Byrne; Ronald E Diehl; Dawn L Hall; Allison M Montalvo; John C Reid; Jennifer M Shipman; Bradley W Thomas; Sanjeev K Munshi; Paul L Darke; Hua-Poo Su
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

5.  Divergent Inhibitor Susceptibility among Airway Lumen-Accessible Tryptic Proteases.

Authors:  Shilpa Nimishakavi; Wilfred W Raymond; Dieter C Gruenert; George H Caughey
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

6.  Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study.

Authors:  Ma'mon M Hatmal; Omar Abuyaman; Mutasem Taha
Journal:  Comput Struct Biotechnol J       Date:  2021-08-19       Impact factor: 7.271

7.  Measuring the Concentration of Serum Syndecan-1 to Assess Vascular Endothelial Glycocalyx Injury During Hemodialysis.

Authors:  Keigo Kusuzawa; Keiko Suzuki; Hideshi Okada; Kodai Suzuki; Chihiro Takada; Soichiro Nagaya; Ryu Yasuda; Haruka Okamoto; Takuma Ishihara; Hiroyuki Tomita; Yuki Kawasaki; Toru Minamiyama; Ayane Nishio; Hirotsugu Fukuda; Takuto Shimada; Yuto Tamaoki; Tomoki Yoshida; Yusuke Nakashima; Naokazu Chiba; Genki Yoshimura; Ryo Kamidani; Tomotaka Miura; Hideaki Oiwa; Fuminori Yamaji; Yosuke Mizuno; Takahito Miyake; Yuichiro Kitagawa; Tetsuya Fukuta; Tomoaki Doi; Akio Suzuki; Takahiro Yoshida; Nobuyuki Tetsuka; Shozo Yoshida; Shinji Ogura
Journal:  Front Med (Lausanne)       Date:  2021-12-23

8.  Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat.

Authors:  Tim Hempel; Lluís Raich; Simon Olsson; Nurit P Azouz; Andrea M Klingler; Markus Hoffmann; Stefan Pöhlmann; Marc E Rothenberg; Frank Noé
Journal:  Chem Sci       Date:  2020-11-13       Impact factor: 9.825

Review 9.  The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.

Authors:  Lukas Wettstein; Frank Kirchhoff; Jan Münch
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

10.  Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.

Authors:  Markus Hoffmann; Heike Hofmann-Winkler; Joan C Smith; Nadine Krüger; Lambert K Sørensen; Ole S Søgaard; Jørgen Bo Hasselstrøm; Michael Winkler; Tim Hempel; Lluís Raich; Simon Olsson; Takashi Yamazoe; Katsura Yamatsuta; Hirotaka Mizuno; Stephan Ludwig; Frank Noé; Jason M Sheltzer; Mads Kjolby; Stefan Pöhlmann
Journal:  bioRxiv       Date:  2020-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.